Symbols / ANVS $2.51 -8.58%
ANVS Chart
About
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 66.39M |
| Enterprise Value | 58.16M | Income | -28.85M | Sales | — |
| Book/sh | 0.62 | Cash/sh | 0.69 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.32 | PEG | — |
| P/S | — | P/B | 4.04 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 5.37 |
| Current Ratio | 5.80 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.43 | EPS next Y | -1.08 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 17:00 | ROA | -106.03% |
| ROE | -220.61% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.50M |
| Shs Float | 24.26M | Short Float | 11.57% | Short Ratio | 7.28 |
| Short Interest | — | 52W High | 5.50 | 52W Low | 1.11 |
| Beta | 1.31 | Avg Volume | 427.35K | Volume | 188.61K |
| Target Price | $11.67 | Recom | Strong_buy | Prev Close | $2.74 |
| Price | $2.50 | Change | -8.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.67
Mean price target
2. Current target
$2.51
Latest analyst target
3. DCF / Fair value
$-10.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.51
Low
$8.00
High
$17.00
Mean
$11.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2025-09-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-06-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-05-15 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2025-02-10 | down | D. Boral Capital | Buy → Hold | — |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $21 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-25 | up | Maxim Group | Hold → Buy | $25 |
| 2024-08-15 | main | EF Hutton | Buy → Buy | $21 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-13 | init | EF Hutton | — → Buy | $21 |
| 2024-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-07-11 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-07-02 | reit | Rodman & Renshaw | Buy → Buy | $67 |
| 2024-06-12 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-06-04 | init | Rodman & Renshaw | — → Buy | $67 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-04-30 | main | Canaccord Genuity | Buy → Buy | $26 |
| 2024-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $30 |
- $ANVS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 19
- Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan Mon, 16 Mar 2026 21
- ANVS Technical Analysis & Stock Price Forecast - Intellectia AI ue, 17 Mar 2026 16
- Annovis Bio (NYSE:ANVS) Stock Price Down 8.5% - What's Next? - MarketBeat Fri, 06 Mar 2026 08
- Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate - Annovis Bio (NYSE:ANVS) - Benzinga Mon, 16 Mar 2026 11
- New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026 - Stock Titan ue, 03 Mar 2026 08
- We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance Sun, 22 Jun 2025 07
- Friday 12/12 Insider Buying Report: ANVS, ECL - Nasdaq Fri, 12 Dec 2025 08
- $ANVS stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 13 Jan 2026 08
- Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat Fri, 13 Mar 2026 21
- $ANVS stock is up 4% today. Here's what we see in our data. - Quiver Quantitative Fri, 28 Nov 2025 08
- Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat Fri, 13 Mar 2026 05
- Annovis Bio (NYSE: ANVS) Reaffirms FDA-Aligned Phase 3 Alzheimer's Trial, Plans PDD Meeting - Stock Titan ue, 18 Nov 2025 08
- Insider Purchase: Director at $ANVS Buys 15,000 Shares - Quiver Quantitative ue, 18 Nov 2025 08
- Insider Purchase: President & CEO of $ANVS Buys 97,561 Shares - Quiver Quantitative Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 45000 | 193794 | — | Purchase at price 4.24 - 4.34 per share. | HOFFMAN MICHAEL B | Director | — | 2025-12-08 00:00:00 | D |
| 1 | 39200 | 159886 | — | Purchase at price 3.85 - 4.15 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-24 00:00:00 | D |
| 2 | 39200 | 159886 | — | Purchase at price 3.85 - 4.15 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-24 00:00:00 | D |
| 3 | 20000 | 69900 | — | Purchase at price 3.49 - 3.50 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-21 00:00:00 | D |
| 4 | 15000 | 31650 | — | Purchase at price 2.11 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-14 00:00:00 | D |
| 5 | 97561 | 200000 | — | Purchase at price 2.05 per share. | MACCECCHINI MARIA-LUISA | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 6 | 975610 | 2000000 | — | Purchase at price 2.05 per share. | HOFFMAN MICHAEL B | Director | — | 2025-10-28 00:00:00 | D |
| 7 | 7142 | 1000 | — | Conversion of Exercise of derivative security at price 0.14 per share. | BRUCK CLAUDINE | Director | — | 2025-09-10 00:00:00 | D |
| 8 | 15000 | 34350 | — | Stock Award(Grant) at price 2.28 - 2.30 per share. | HOFFMAN MICHAEL B | Director | — | 2025-08-29 00:00:00 | D |
| 9 | 18645 | 48280 | — | Stock Award(Grant) at price 2.57 - 2.60 per share. | HOFFMAN MICHAEL B | Director | — | 2025-08-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -30.32M | -33.20M | -25.51M | -14.50M |
| TotalUnusualItems | 3.63M | -11.84M | ||
| TotalUnusualItemsExcludingGoodwill | 3.63M | -11.84M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.59M | -56.20M | -25.33M | -14.49M |
| EBITDA | -26.69M | -45.04M | -25.51M | -14.50M |
| EBIT | -26.69M | -45.04M | -25.51M | -14.50M |
| NetInterestIncome | -1.52M | 667.90K | 182.71K | 13.34K |
| InterestIncome | 331.85K | 667.90K | 182.71K | 13.34K |
| NormalizedIncome | -28.22M | -44.37M | -25.33M | -14.49M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.59M | -56.20M | -25.33M | -14.49M |
| TotalExpenses | 26.69M | 45.04M | 25.51M | 14.50M |
| TotalOperatingIncomeAsReported | -26.69M | -45.04M | -25.51M | -14.54M |
| DilutedAverageShares | 12.24M | 9.02M | 8.16M | 7.63M |
| BasicAverageShares | 12.18M | 9.02M | 8.16M | 7.63M |
| DilutedEPS | -2.31 | -6.23 | -3.10 | -1.90 |
| BasicEPS | -2.02 | -6.23 | -3.10 | -1.90 |
| DilutedNIAvailtoComStockholders | -28.22M | -56.20M | -25.33M | -14.49M |
| AverageDilutionEarnings | -3.63M | 0.00 | ||
| NetIncomeCommonStockholders | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncome | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncomeIncludingNoncontrollingInterests | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncomeContinuousOperations | -24.59M | -56.20M | -25.33M | -14.49M |
| PretaxIncome | -24.59M | -56.20M | -25.33M | -14.49M |
| OtherIncomeExpense | 3.63M | -11.84M | ||
| GainOnSaleOfSecurity | 3.63M | -11.84M | ||
| NetNonOperatingInterestIncomeExpense | -1.52M | 667.90K | 182.71K | 13.34K |
| TotalOtherFinanceCost | 1.85M | |||
| InterestIncomeNonOperating | 331.85K | 667.90K | 182.71K | 13.34K |
| OperatingIncome | -26.69M | -45.04M | -25.51M | -14.50M |
| OperatingExpense | 26.69M | 45.04M | 25.51M | 14.50M |
| OtherOperatingExpenses | -36.75K | |||
| ProvisionForDoubtfulAccounts | 0.00 | 0.00 | 0.00 | |
| ResearchAndDevelopment | 20.00M | 38.79M | 16.52M | 8.48M |
| SellingGeneralAndAdministration | 6.70M | 6.24M | 9.00M | 6.06M |
| GeneralAndAdministrativeExpense | 6.70M | 6.24M | 9.00M | 6.06M |
| OtherGandA | 6.70M | 6.24M | 9.00M | 6.06M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 14.14M | 10.52M | 8.16M | 8.10M |
| ShareIssued | 14.14M | 10.52M | 8.16M | 8.10M |
| TangibleBookValue | 9.31M | -7.75M | 28.32M | 44.49M |
| InvestedCapital | 9.31M | -7.75M | 28.32M | 44.49M |
| WorkingCapital | 10.04M | 5.93M | 28.32M | 44.49M |
| NetTangibleAssets | 9.31M | -7.75M | 28.32M | 44.49M |
| CommonStockEquity | 9.31M | -7.75M | 28.32M | 44.49M |
| TotalCapitalization | 9.31M | -7.75M | 28.32M | 44.49M |
| TotalEquityGrossMinorityInterest | 9.31M | -7.75M | 28.32M | 44.49M |
| StockholdersEquity | 9.31M | -7.75M | 28.32M | 44.49M |
| RetainedEarnings | -134.85M | -110.26M | -54.05M | -28.73M |
| AdditionalPaidInCapital | 144.16M | 102.51M | 82.38M | 73.22M |
| CapitalStock | 1.41K | 1.05K | 816.00 | 810.00 |
| CommonStock | 1.41K | 1.05K | 816.00 | 810.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.62M | 17.96M | 7.70M | 1.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 737.00K | 13.68M | 0.00 | 0.00 |
| DerivativeProductLiabilities | 737.00K | 13.68M | 0.00 | |
| CurrentLiabilities | 3.88M | 4.28M | 7.70M | 1.51M |
| PayablesAndAccruedExpenses | 3.88M | 4.28M | 7.70M | 1.51M |
| CurrentAccruedExpenses | 1.58M | 2.99M | 3.74M | 818.44K |
| Payables | 2.31M | 1.29M | 3.96M | 688.07K |
| AccountsPayable | 2.31M | 1.29M | 3.96M | 688.07K |
| TotalAssets | 13.93M | 10.21M | 36.02M | 46.00M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 13.93M | 10.21M | 36.02M | 46.00M |
| PrepaidAssets | 3.37M | 4.45M | 7.64M | 315.46K |
| CashCashEquivalentsAndShortTermInvestments | 10.55M | 5.75M | 28.38M | 45.69M |
| CashAndCashEquivalents | 10.55M | 5.75M | 28.38M | 45.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -21.89M | -39.97M | -17.31M | -9.13M |
| IssuanceOfCapitalStock | 18.67M | 16.89M | 0.00 | 46.65M |
| EndCashPosition | 10.55M | 5.75M | 28.38M | 45.69M |
| BeginningCashPosition | 5.75M | 28.38M | 45.69M | 8.07M |
| ChangesInCash | 4.80M | -22.62M | -17.31M | 37.61M |
| FinancingCashFlow | 26.69M | 17.34M | 4.61K | 46.74M |
| CashFlowFromContinuingFinancingActivities | 26.69M | 17.34M | 4.61K | 46.74M |
| ProceedsFromStockOptionExercised | 8.03M | 458.38K | 4.61K | 95.10K |
| NetCommonStockIssuance | 18.67M | 16.89M | 0.00 | 46.65M |
| CommonStockIssuance | 18.67M | 16.89M | 0.00 | 46.65M |
| OperatingCashFlow | -21.89M | -39.97M | -17.31M | -9.13M |
| CashFlowFromContinuingOperatingActivities | -21.89M | -39.97M | -17.31M | -9.13M |
| ChangeInWorkingCapital | 681.71K | -228.60K | -1.14M | 657.35K |
| ChangeInPayablesAndAccruedExpense | -398.12K | -3.42M | 6.19M | 928.13K |
| ChangeInAccruedExpense | -1.41M | -751.01K | 2.92M | 581.92K |
| ChangeInPayable | 1.01M | -2.67M | 3.27M | 346.22K |
| ChangeInAccountPayable | 1.01M | -2.67M | 3.27M | 346.22K |
| ChangeInPrepaidAssets | 1.08M | 3.19M | -7.33M | -270.79K |
| ChangeInReceivables | 0.00 | |||
| OtherNonCashItems | 1.80M | |||
| StockBasedCompensation | 3.84M | 4.63M | 9.15M | 4.70M |
| OperatingGainsLosses | -3.63M | 11.84M | ||
| GainLossOnInvestmentSecurities | -3.63M | 11.84M | ||
| NetIncomeFromContinuingOperations | -24.59M | -56.20M | -25.33M | -14.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ANVS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|